Secondary cytoreduction for relapsed ovarian cancer
Volume: 22, Issue: 6, Pages: e232 - e232
Published: Jun 1, 2021
Abstract
In the SOC-1 trial, Tingyan Shi and colleagues 1 Shi T Zhu J Feng Y et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22: 439-449 Summary Full Text Full Text PDF PubMed Scopus (9) Google Scholar showed that secondary cytoreduction followed by chemotherapy improved progression-free...
Paper Details
Title
Secondary cytoreduction for relapsed ovarian cancer
Published Date
Jun 1, 2021
Volume
22
Issue
6
Pages
e232 - e232
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History